Bionime Corporation (4737-TW) proudly announces that its RIGHTEST iFree Continuous Glucose Monitoring (CGM) System has received the prestigious 2025 Taiwan Excellence Gold Award, following its recognition with the Gold Award for Innovative Medical Device Technology at the 2024 Taipei Biotech Awards.

Innovative Glucose Monitoring

As Taiwan’s first domestically developed and approved CGM system, RIGHTEST iFree CGM offers 10 days of continuous glucose monitoring, real-time data transmission, and comprehensive glucose insights through a smartphone app, helping users better understand and manage their glucose levels.

Advanced Manufacturing Excellence

Backed by nearly a decade of R&D, Bionime has filed over 400 patent applications worldwide, with 237 patents granted. Its manufacturing process integrates over 200 production steps, advanced automation, and intelligent manufacturing systems aligned with Industry 4.0 standards.

Committed to Accessible Diabetes Care

Guided by its Six Sigma (6σ) quality culture, Bionime continues to advance innovative, reliable, and affordable CGM solutions, making glucose monitoring more accessible and empowering people to live healthier lives with confidence.